Research – February 2026 - Food Allergy Canada

Find out about Palforzia^® peanut oral immunotherapy exiting the market worldwide, and get the latest updates on sublingual epinephrine film. Find out how you can participate in a research opportunity for children with tree nut allergy. Plus, read our mythbuster on co-factors and allergic reactions.

Research: Palforzia^® peanut oral immunotherapy powder exiting the market worldwide

Palforzia^®, an oral powder prescription immunotherapy treatment for children with peanut allergy, is exiting the market worldwide. Manufacturer Stallergenes Greer is discontinuing the commercialization of the treatment as of July 31, 2026, and has noted that this voluntary discontinuation is not related to product safety, quality, or efficacy. This exit mostly impacts the U.S., U.K., and some European countries.

Please note, this product was not available in Canada; Canadian allergists recommend using real foods for oral immunotherapy.

Visit palforzia.com for more information

Research: U.S. FDA review of under-the-tongue (sublingual) epinephrine film

The U.S. Food and Drug Administration (FDA) has asked for more information before approving Anaphylm^™, an under-the-tongue (sublingual) epinephrine film being developed to treat anaphylaxis.

In its response, the FDA raised concerns about how easy the product is to use in an emergency — including opening the package and placing the film correctly under the tongue. The FDA also requested additional research to understand how any changes to the packaging or instructions might affect use.

Aquestive Therapeutics, the company developing Anaphylm^™, says it expects to address these issues quickly and plans to resubmit its application to the FDA later this year. It also plans to apply for approvals in Europe and Canada by the end of the year.

We will continue to share updates on the status of new treatment options internationally and on our advocacy efforts for access to epinephrine device options in Canada.  

Read Aquestive’s news release

Research study: Call for participation for children with tree nut allergy

A research study is underway in Hamilton, Ontario. The researchers are seeking children aged 1-16 years who have been diagnosed with tree nut allergy, specifically to cashew, pistachio, walnut, pecan, almond, or hazelnut.

The study is testing different immunotherapies to desensitize a person with tree nut allergy by repeated exposures to very small amounts of tree nut through sublingual immunotherapy (SLIT) or low-dose oral immunotherapy (IdOIT). SLIT is when a food allergen is placed under the tongue and OIT is when a food allergen is eaten.

Food Allergy Canada is involved in this research through a patient/caregiver partnership where we provide input on the design of the research, review research outcomes, and ensure the patient perspective is considered.

Read additional details about the study from the research team. To learn more about the study and if your child is eligible to participate, complete this form or email eia@mcmaster.ca.

Please share with others whose children have tree nut allergy.

Learn more

Mythbuster: Can co-factors affect how someone might react to their food allergen?

FACT: Yes, co-factors can lower the threshold, the amount of the allergen at which one reacts, or can speed up the progression of a reaction, making it more severe. Common co-factors include exercise, illness, and uncontrolled asthma.

It’s important to be aware of potential co-factors and take them into account when managing your food allergy. As always, be familiar with the symptoms of anaphylaxis and prepared with epinephrine if a reaction happens.